On June 9, 2026, a new trial listing for carbetocin was registered on ClinicalTrials.gov. The study is titled "Carbetocin Monotherapy Versus Carbetocin Plus Oxytocin Infusion in Elective Cesarean Delivery: A Non-Inferiority Trial." It is registered as NCT07636421 and classified as a Phase 4 study.
According to the listing, the trial's current status is not yet recruiting. The study is designed as a non-inferiority trial, meaning it aims to determine whether carbetocin monotherapy performs no worse than the combination of carbetocin plus oxytocin infusion in the context of elective cesarean delivery.
No participant enrollment has begun as of the listing date. No results, outcomes, or efficacy data have been posted for this trial at this time. The registration reflects only the planned design and objectives of the study as stated in the record.
Carbetocin's regulatory status is noted as unapproved research use in this context. Readers should treat this listing as a record of a planned clinical trial rather than an indication of confirmed safety or effectiveness. Further updates may follow as the trial's recruitment status changes.
For more background on this compound, readers can consult the compound overview page.